News | Heart Valve Technology | March 14, 2019

ACC Launches Transcatheter Valve Certification

Certificate pairs with established national clinical databases to monitor patient safety, real-world outcomes related to transcatheter valve replacement and repair procedures

ACC Launches Transcatheter Valve Certification

March 14, 2019 — Beginning in mid-2019, hospitals performing transcatheter valve repair and replacement will be able to apply for the American College of Cardiology’s new Transcatheter Valve Certification. The certification was announced at the American College of Cardiology (ACC) Quality Summit in New Orleans.

The ACC’s Transcatheter Valve Certification is an external review and certification process that will assist hospitals in meeting standards for multidisciplinary teams, formalized training, shared decision-making and registry performance. Participation in established national clinical databases, such as the Society of Thoracic Surgeons (STS)/ACC TVT (Transcatheter Valve Therapy) Registry, is required for hospitals interested in achieving Transcatheter Valve Certification.

“ACC’s Transcatheter Valve Certification tool merges the latest science and process improvement methodologies,” said Phillip D. Levy, M.D., FACC, chair of the ACC Accreditation Management Board. “This certification incorporates recent guidelines and expert consensus statements regarding the care of patients requiring transcatheter valve therapies.”

The certification uses established national clinical measures data to support clinical decisions and links process improvement to patient outcomes. This ensures the certification is responsive to the resourcing at hospitals focused and committed to performance improvement in patient care delivery and coordination post-procedure. By connecting the data to opportunities for improvement, Transcatheter Valve Certification promotes consistent processes across the care continuum and better patient outcomes.

Hospitals that achieve Transcatheter Valve Certification will learn best practices for implementing evidence-based medicine to support decision-making in the care of individual patients and be able to track key performance metrics to better identify opportunities for improvement.

For more information: www.accreditation.acc.org

Related Content

The opening late-breaking trial at ACC 2019 is the Apple Heart Study, a large-scale, app-based study to identify atrial fibrillation using a smartwatch. Earlier, smaller trials showed this approach might be used in a population health application to proactively identify AFib patients earlier.

Feature | ACC | March 19, 2019
The American College of Cardiology (ACC) released a list of the late
A patient who received HeartMate III LVAD system at ACC.18. The HeartMate 3 was the topic of of the the key late-breaking trials at #ACC18

A patient who received the HeartMate III LVAD system showing off his external battery pack. He served as a patient ambassador in the Abbott booth at ACC.18. The HeartMate III, with its magnetic levitated pump, showed a big reduction in clotting over previous LVADs in a key late-breaking trial at this year's conference.

Feature | ACC | March 27, 2018 | Dave Fornell
There were several notable presentations of new data on cardiovascular technologies at the recent 2018 American Colle
Drug Stops Dangerous Bleeding in Patients Taking Factor Xa Inhibitors

Connolly 

News | ACC | March 22, 2018
March 22, 2018 — The experimental drug...
Videos | ACC | March 21, 2018
DAIC Editor Dave Fornell takes a tour of some of the most interesting new technologies on the expo floor at
ACC 2018 Late-Breaking Trials Announced
News | ACC | March 21, 2018
Here is a list of the American College of Cardiology (ACC) 2018 annual meeting late-breaking clinical trials presente
Inhaled Therapy Ineffective in Difficult-to-Treat Heart Failure at ACC 2018.

Image from presentation, "Inorganic Nitrite Delivery to Improve Exercise Capacity in HFpEF: The INDIE-HFpEF Trial," Borlaug

News | ACC | March 20, 2018
March 20, 2018 — Four weeks of treatment with a novel inhaled medication failed to improve exercise capacity, daily a
More Deaths, Strokes Seen with Perioperative Beta Blocker One Year After Surgery

Image from presentation, "1-Year outcomes of perioperative beta-blockade in patients undergoing noncardiac surgery," Devereaux 

News | ACC | March 20, 2018
March 20, 2018 — During the 12 months after undergoing noncardiac surgery, patients with or at risk for heart disease
Trial for Gout Drug Meets Primary Endpoint, Raises Safety Concerns, image shows a CT scan showing gout in the knees.
News | ACC | March 20, 2018
March 20, 2018 — Febuxostat, a gout dr...
Canakinumab Doesn’t Prevent Prediabetes from Progressing to Diabetes according to a late-breaking study at ACC 2018.
News | ACC | March 20, 2018
March 20, 2018 — The anti-inflammatory...
Dabigatran Reduces Major Cardiovascular Complications in Patients With Myocardial Injury after Noncardiac Surgery
News | ACC | March 20, 2018
March 20, 2018 — Treatment with the blood-thinning drug dabigatran significantly reduced the risk of death, heart att
Overlay Init